Mediphage Bioceuticals, a preclinical-stage biotechnology company, is developing a next-generation non-viral gene therapy platform based on its proprietary mini string DNA (msDNA) technology. A Toronto-based company, founded in 2016, Mediphage uses a proprietary manufacturing process to develop safe, durable and redosable gene delivery vectors. msDNA is designed to overcome critical challenges facing viral gene therapies and leverage advancements in the delivery of nucleic acids.

Mediphage Bioceuticals Logo



Event details

Date: September 13 - 15, 2021

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


6 in total